Heron Therapeutics, Inc. (HRTX) Financial Statements
Heron Therapeutics, Inc. (HRTX) reported trailing twelve-month revenue of $151.2M (up 1.0% year on year) and net income of -$34.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$12.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HRTXHeron Therapeutics, Inc.Follow HRTX — free
—
Price chart with a free account
- Market cap
- 57.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.5 | 146.0 | 88.6 | 86.3 | 107.7 | 127.0 | 144.3 | 154.9 | 151.2 | |
| Gross profit | 50.0 | 84.3 | 52.4 | 40.3 | 52.8 | 61.9 | 105.6 | 113.6 | 105.9 | |
| Research & development | 140.0 | 167.4 | 174.5 | 130.8 | 82.7 | 39.1 | 16.7 | 12.4 | 12.3 | |
| Operating income | -183.9 | -210.7 | -228.2 | -217.8 | -174.7 | -110.6 | -11.5 | -2.5 | -10.9 | |
| Pre-tax income | -178.8 | -204.7 | -227.3 | -220.7 | -182.0 | -110.6 | -13.6 | -20.2 | -34.0 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -178.8 | -204.7 | -227.3 | -220.7 | -182.0 | -110.6 | -13.6 | -20.2 | -34.0 | |
| Diluted EPS ($) | -2.44 | -2.50 | -2.50 | -2.24 | -1.67 | -0.80 | -0.09 | -0.12 | -0.18 | |
| Diluted shares (mn) | — | — | — | — | 108.9 | 138.1 | 152.4 | 166.7 | — |
USD millions · SEC XBRL
Heron Therapeutics, Inc. — questions
- What is Heron Therapeutics, Inc.'s revenue?
- $151.2M over the twelve months to 2026-06-30, up 1.0% year on year, from its 10-Q and 10-K filings.
- What is Heron Therapeutics, Inc.'s net income?
- -$34.0M over the twelve months to 2026-06-30.
- What is Heron Therapeutics, Inc.'s free cash flow?
- -$12.1M over the twelve months to 2026-06-30.
- What are Heron Therapeutics, Inc.'s diluted earnings per share?
- $-0.18 over the twelve months to 2026-06-30.
Every figure on this page comes from Heron Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.